Cambridge Healthtech Institute’s 6th Annual

Immuno-Oncology Biomarkers and Diagnostics

Predicting and Monitoring Response to Cancer Immunotherapy

August 26-27, 2020

 

Immunotherapy is the most effective therapeutic approach in a variety of advanced and metastatic cancers that the cancer community has seen in decades. However, the success of each of the agents is highly dependent on specific approach for a specific patient population. Therefore, the progress in adoption of cancer immunotherapy requires the development and implementation of robust clinical-grade biomarkers. Once validated, the biomarkers and companion diagnostics for cancer immunotherapy undergo significant market access challenges that include regulatory and reimbursement hurdles. Cambridge Healthtech Institute’s Sixth Annual Immuno-Oncology Biomarkers and Diagnostics conference is designed to bring together clinical immuno-oncologists, researchers from pharmaceutical and biotech companies, and members of the laboratory medicine community to discuss challenges and solutions for bringing to the market and implementing robust and cost-effective companion and complementary assays that improve patient outcomes.

Preliminary Agenda

BIOMARKERS FOR COMBINATION CANCER TRIALS

Combination Trials: HER + and PDL +

Jon Wigginton, MD, CMO, Senior Vice President, Clinical Development, MacroGenics

Blood-Based Biomarkers for Drug Discovery and Patient Selection in Immuno-Oncology

Katie Streicher, PhD, Associate Director, Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca

PREDICTIVE BIOMARKERS AND NEOANTIGENS

Predictive Biomarkers for Immunotherapy in Lung Cancer: Current Status and Future Perspectives

Fred Hirsch, MD, PhD, Executive Director, Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System; Professor of Medicine, Icahn School of Medicine; Associate Director, Tisch Cancer Institute

Personalizing Immunotherapy for Each Cancer Patient

Matthew Davis, PhD, Associate Director, Molecular Biology and Sequencing, Gritstone Oncology

Changing the Light by Mass to Resolve the Immune Profiling of Tumor Tissue and Tumor Associated Immune Cells

Alejandro Francisco-Cruz, MD, PhD, Postdoctoral Fellow, Translational Molecular Pathology, MD Anderson Cancer Center

MDR AND LIQUID BIOPSY

Measurable (‘Minimal’) Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Roland Walter, MD, PhD, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center

Comparing Liquid Biopsy Results and Understanding Sources of Tumor-Plasma Variant Discordance

Brian Dougherty, PhD, MBA, Executive Director, Translational Medicine, Oncology R&D, AstraZeneca

EARLY DETECTION OF CANCER

Leveraging Novel Exosome Nanosensors for Earlier Pancreatic Cancer Detection

Cesar Martin Castro, MD, Director, Cancer Program, MGH Center for Systems Biology, Massachusetts General Hospital/Harvard Medical School

The Advantages and Challenges of Liquid Biopsies for Early Cancer Detection and Screening

Lynn Sorbara, PhD, Program Director, Cancer Biomarkers Research Group, National Cancer Institute (NCI), NIH



* The program is subject to change without notice, due to unforeseen reason.





Premier Sponsor


Corporate Sponsors


> View All Sponsors